Enhance Cardiometabolic Risk Prediction with High-Plex Proteomics

Cardiovascular risk prediction remains one of the toughest barriers in drug development. In this application note, you’ll see how the SomaScan™ Platform’s 27-protein model and SomaSignal™ Tests improve upon traditional clinical scores to provide earlier, more accurate insights. Case studies from Phase 3 semaglutide studies and large validation cohorts demonstrate how proteomic biomarkers are reshaping trial design, highlighting the potential to detect benefits and risks earlier and to design smaller, shorter and more cost-effective studies.

You’ll learn about:

• How multi-protein biomarker models enable earlier detection of cardiovascular risk
• Case studies showing the potential of proteomic surrogate endpoints to accelerate trial timelines
• Evidence from a validated 27-protein model that improves prediction beyond clinical scores
• How SomaScan data captures drug response and lifestyle intervention effects in clinical trials
• How proteomics can reveal both on- and off-target drug effects earlier in clinical outcomes